A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie de Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye
doi: https://doi.org/10.1101/2020.12.01.20239574
Suresh Kumar
1MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital, New Delhi, Delhi, India
Rosemarie de Souza
2Topiwala National Medical College & B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India
Milind Nadkar
3Seth GS medical college and KEM Hospital, Mumbai, Maharashtra, India
Randeep Guleria
4All India Institute of Medical Sciences, New Delhi, Delhi, India
Anjan Trikha
4All India Institute of Medical Sciences, New Delhi, Delhi, India
Shashank R. Joshi
5Indian College of Physicians and Lilavati Hospital, Mumbai, Maharashtra, India
Subramanian Loganathan
6Biocon Biologics Indian Ltd, Bengaluru, Karnataka, India
Sivakumar Vaidyanathan
6Biocon Biologics Indian Ltd, Bengaluru, Karnataka, India
Ashwani Marwah
6Biocon Biologics Indian Ltd, Bengaluru, Karnataka, India
Sandeep N. Athalye
6Biocon Biologics Indian Ltd, Bengaluru, Karnataka, India
Data Availability
All data reported in the manuscript are present in the company database.
Posted December 02, 2020.
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie de Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye
medRxiv 2020.12.01.20239574; doi: https://doi.org/10.1101/2020.12.01.20239574
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie de Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye
medRxiv 2020.12.01.20239574; doi: https://doi.org/10.1101/2020.12.01.20239574
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (678)
- Anesthesia (182)
- Cardiovascular Medicine (2678)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12310)
- Forensic Medicine (10)
- Gastroenterology (769)
- Genetic and Genomic Medicine (4158)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2694)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2071)
- Ophthalmology (596)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1131)
- Primary Care Research (461)
- Public and Global Health (6578)
- Radiology and Imaging (1420)
- Respiratory Medicine (876)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)